# A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

> **NCT07015398** · PHASE1 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 132 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Pirfenidone
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT07015398
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-30
- **Primary completion:** 2025-09-12
- **Final completion:** 2025-09-26
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015398, "A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07015398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*